Vertex posted first-quarter adjusted earnings per share of $4.06, with revenue rising 3% year-over-year to $2.77 billion.

Vertex Pharmaceuticals stock was falling sharply Tuesday after the biotech company reported first-quarter earnings that ...

Vertex Pharmaceuticals' (NASDAQ: VRTX) remarkable momentum came to a screeching halt this week. The big biotech stock had ...

Vertex's diversification efforts are most visible in the progress of its pain management portfolio. Read why I rate VRTX ...

We recently published a list of 21 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Vertex ...

Vertex Pharmaceuticals reported disappointing Q1 revenue and earnings. Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) were ...

EPS and sales below estimates but raised its 2025 revenue outlook, driven by CF drug demand and new product launches in the U ...

Vertex Pharmaceuticals (VRTX) and Neurocrine Biosciences (NBIX) shares are moving sharply after their respective earnings ...

Vertex Pharmaceuticals hit a rough patch in Q1, reporting weaker-than-expected earnings and halting an early mRNA cystic ...

Copyright © 2025 MarketWatch, Inc. All rights reserved.

Vertex Pharmaceuticals is pressing pause on a phase 1/2 cystic fibrosis (CF) trial over a tolerability issue, while reporting ...

As of July 2024, the strategy allocated 28% of assets to medical technology, 27% to pharmaceuticals, 24% to healthcare services, and 22% to biotech—all within 5 percentage points of the index.